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Background: 70–80% of sporadic endometrial carcinomas are defined as endometrioid carcinoma (EC). Early-stage,
well differentiated endometrial carcinomas usually retain expression of estrogen and progesterone receptors
(ER and PR, respectively), as advanced stage, poorly differentiated tumors often lack one or both of these receptors.
Well-described EC prognosis includes tumor characteristics, such as depth of myometrial invasion. Therefore, in the
current study, we evaluated the expression profile of ER and PR isoforms, including ER-α, PR-A and PR–B, in
correlation to EC tumor histological depth.
Methods: Using immunohistochemistry and image analysis software, the expression of ER-α, PR-A, PR–B and Ki67
was assessed in endometrial stroma and epithelial glands of superficial, deep and extra-tumoral sections of 15
paraffin embedded EC specimens, and compared to 5 biopsies of non-malignant endometrium.
Results: Expression of PR-A and ER-α was found to be lower in EC compared to nonmalignant tissue, as the stromal
expression was dramatically reduced compared to epithelial cells. Expression ratios of both receptors were
significantly high in superficial and deep portions of EC; in non-tumoral portion of EC were close to the ratios of
nonmalignant endometrium. PR-B expression was low in epithelial glands of EC superficial and deep portions, and
high in the extra-tumoral region. Elevated PR-B expression was found in stroma of EC, as well.
Conclusions: The ratio of ER-α and PR-A expression in the epithelial glands and the stroma of EC biopsies may
serve as an additional parameter in the histological evaluation of EC tumor.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1155060506119016
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Approximately 70–80% of sporadic endometrial carcin-
omas are distinguished as type I carcinomas, which is
the most common malignancy in female reproductive
tract and defined as EC. Well-described EC prognosis
includes stage of disease at the time of diagnosis, his-
tologic type, degree of tumor differentiation, depth of
myometrial invasion and lymphovascular space invasion.
The glandular epithelium from which the cancer arises
is hormone responsive, expressing both PRs and ERs [1].
EC often develops from endometrial hyperplasia, which* Correspondence: shaleve@technion.ac.il
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article, unless otherwise stated.is attributed to prolonged exposure to estrogen in the
absence of (unopposed) sufficient progesterone [2], and
is often well differentiated and noninvasive or superfi-
cially myoinvasive, rarely producing metastases and ex-
pressing ER [3]. Whereas early-stage, well differentiated
EC usually retain expression of both receptors, advanced
stage, poorly differentiated tumors often lack one or
both of these receptors, which has been correlated in
many studies with a poor prognosis [4,5]. The majority
of estrogen-dependent carcinomas occur during the
post-menopausal period, when active sex steroids are
not produced by the ovaries. Therefore, in-situ estrogen
metabolism has a crucial role in the development and
progression of EC in this period [6]. Both estrogen and
progesterone exert their effect through intra-and extra-
nuclear receptors. ER exists in 2 main forms, ER-α andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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spectively, binding the same estrogen response elements
(EREs) and regulate similar sets of genes [7]. However,
ER-α and ER-β has a distinct pattern of expression in
the tissues [8], which varies during cellular proliferation
and differentiation [9]. ER-α is required for the basic de-
velopment of estrogen sensitive tissues and ER-β is re-
quired for organization and adhesion of epithelial cells
and hence for differentiated tissue morphology and its
functional maturation [10].
PR has been implicated in the development of endo-
metrial cancer, as well. The single-copy PR gene uses
separate promoters and translational start sites to pro-
duce two isoforms, PR-A and -B [11], which are in fact
two functionally distinct transcription factors [12], medi-
ating their own response genes and physiological effects
with little overlap [13]. The physiological roles of pro-
gesterone in the regulation of endometrial tissue are, in
general, considered to antagonize estrogen-mediated
cell proliferation and to induce cellular differentiation
[14,15]. Loss of total PR expression was found in well
and in poorly differentiated EC, and was related to PR-A
[16-18]. Highly malignant forms of endometrial, cervical
and ovarian cancers have been correlated with over-
expression of PR-B [19,20]. Another examined marker in
this study is Ki67, a widely used nuclear marker
expressed during all active phases of the cell cycle, but
absent from resting cells (G0) [21], and therefore its ex-
pression is examined in order to assess proliferative ac-
tivity. High Ki-67 expression was found in various types
of endometrial carcinomas [22] and correlates with
histological grade, depth of myometrial invasion and risk
of recurrence [23-25]. In the current study, the common
examination of receptors profile in the epithelial cells of
the tumor was under focus by the evaluation of ER and
PR isoforms expression as well as Ki67 in the stromal
cells and the epithelial glands of EC specimens. Profile




15 formalin fixed paraffin-embedded (FFPE) tumor sam-
ples from patients diagnosed with grade 1 and 2 EC be-
tween March 2007 and February 2010 were obtained
from patients undergoing surgery for hysterectomy in
the Gynecology department at Emek Medical Center
(Afula, Israel). The clinical stage, histological type and
tumor grade were assessed using the Federation of
Gynecology and Obstetrics (FIGO; 2009) system of clas-
sification. The mean age of the patients was 66.2 years
with a range from 43 to 87 years. Data of patients is de-
tailed in Additional file 1. Superficial (block 1) and deep
(block 2) portions of the tumor, as well as extra-tumoraltissue (block 3) origin in the same specimen, were exam-
ined. While the superficial portion represents the surface
of the tumor, the deep portion (block 2) represents the
myometrial invasion of the tumor, which is an important
parameter for the tumor’s characterization, prognosis
and adapted treatment. 5 FFPE samples of nonmalignant
(normal) endometrial tissue were obtained in the same
procedure. Biopsies were numbered, diagnosed and stored
in the Emek Cancer Diagnosis and Research Institute
(ECDRI). The study was approved by the local ethical
committee, Emek Medical Center (Institutional ethical
board).
Tissue processing
Tissues were fixed in 10% paraformaldehyde, processed
routinely and embedded in paraffin. Sections (2 μm)
were mounted on superfrost slides. Hematoxylin/eosin
staining was used for histological evaluation under light
microscope. Sequential sections were used for ER-α, PR-
A, PR-B and Ki67 stainings.
Immunohistochemistry
The immunostains were performed on an automated
stainer (XT; Ventana Systems, Phoenix, AZ). The pri-
mary antibody incubation time for all assays was 32 mi-
nutes after antigen retrieval in Tris based buffer
(60 minutes at 95–100°C). Anti-ER-α antibody clone H-
184 (sc-7207, Santa-Cruz), anti-PR antibody clone 16
(NCL-PGR-312, Novocastra), anti-PR-B antibody clone
B-30 (sc-811, Santa-Cruz) and anti-Ki67 antibody clone
ZB11 (18-0192Z, Invitrogen) were used. The detection
reaction used the iVIEW DAB detection kit (manufac-
turer-recommended protocol). Hematoxylin counter-
stain was used for color development.
Expression of ER-α, PR-A and PR-B using image analysis
Expression assessment of ER-α, PR-A and Ki67 was per-
formed by scoring based on the percentage of stained
cells and the intensity of nuclear stain, according to the
method described by Carcangiu et al. [26]. Pictures of
sections mounted for ER-α, PR-A and PR-B were taken
using DP70 Olympus camera. The expression level in
the stroma and in the epithelial glands of endometrial
tissues was evaluated and compared (Epithelial glands/
Stroma), using the image analysis software Image-Pro
Plus (version 4.5.1 for Windows 98/2000/XP/NT 4.0,
Media Cybernetics Inc., Bethesda, MD, USA). The epi-
thelial glands/stroma values were examined as a refer-
ence tool that presents the relative expression in both
glands and stroma cells.
Statistical analysis
The data was expressed as mean ± standard deviation of
mean (SD). Differences in the parameters were evaluated
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be significant.
Results
ER-α, PR-A and Ki67 scoring
Scoring levels of ER-α, PR-A and Ki67, shown in Table 1
and in Table 2, reflects the common assessment of
markers expression, which includes counting of stained
epithelial cells detected in 10 high power fields (X40).
Average of stained cells is represented by percents. Scor-
ing shows lower expression of ER-α and PR-A in most
EC biopsies in both superficial (ER-α 71.7 ± 25.6; PR-A
74.7 ± 29.0) and deep (ER-α 64.7 ± 29.2; PR-A 71.7 ±
29.3) portions, while most extra-tumoral biopsies retains
the expression level observed in the nonmalignant tis-
sues (ER-α 90.7 ± 18.3; PR-A 93.7 ± 13.9 in extra-tumoral
portion of EC). The expression assessment of Ki67 in EC
is also aberrant, and was found to be higher in most
superficial EC biopsies (45.7 ± 15.7) than in nonmalig-
nant endometrial specimens.
Expression of ER-α in EC
Results show reduced ER-α expression in all portions of
EC (Figure 1). Superficial portion was found to be af-
fected the most, as well as the stroma cells of all por-
tions. Expression ratio (Glands/stroma) in the surface of
EC specimens was found to be significantly higher
(28.15 ± 6.72) than in the nonmalignant specimens (4.71
± 1.51). The ratio is lower in the deep portion of the
tumor (14.31 ± 2.52). Extra-tumoral portion shows a ra-
tio close to the nonmalignant tissue (3.6 ± 0.66).
Expression of PR-A in EC
PR-A expression was previously found to be highly corre-
lated with the expression of ER [27]. Our results, shown
in Figure 2, are supportive of this postulation, as the pat-
tern of PR-A expression shows the same trend in the dif-
ferent portions of EC specimens as ER-α, as well as the
ratio of expression (Glands/stroma) (Superficial 56.42 ±
13.55; Deep 19.03 ± 5.43; Extra-tumoral 5.84 ± 0.9).
Expression of PR-B in EC
Whereas non-ligated ER-α and PR-A are localized pre-
dominantly in the nucleus, PR-B is often cytoplasmic as
well as nuclear (Figure 3) [28,29]; therefore, its detection
was more complex, and precision was harder to achieve.
In this state, the calculation of expression ratio was notTable 1 Scoring of ER-α, PR-A and Ki67 in epithelium of supe
ER-α (mean of % positive cells) PR-A (mea
Superficial Deep Extra-tumoral Superficial
Mean (± SD) 71.7(±25.6) 64.7(±29.2) 90.7(±18.3) 74.7(±29.0) 7
Range 20-100 0-100 50-100 20-100informative. In the epithelial glands PR-B showed a di-
verse expression, and was found to be higher in the
stroma cells of all EC portions (Superficial 132% ± 25%;
Deep 166% ± 36%; Extra-tumoral 157% ± 36%).
Discussion
Molecular tumor classification, which includes PR and
ER expression, is an integral part of the disease charac-
teristics. The presence of steroid receptors ER-α, PR-A
and PR-B has been quantitatively associated with histo-
logic differentiation [30,31], response to therapy [32] and
metastatic potential [33]. ER-α expression was found to
be decreased in EC [18,34] and is further decreased as
EC grading is advanced [35-38]. In correlation, our re-
sults demonstrate significantly reduced expression of
ER-α in both glands and stroma of endometrioid tumor
in relation to non-malignant endometrial tissue (Figure 1).
The expression of ER-α is lower in the stroma than in
the glands of EC, indicating that stroma cells are signifi-
cantly more affected than the epithelial cells. ER-β
quantification faced technical problems and therefore
was not assessed in the current study. Loss of ER sug-
gests an advanced molecular pathology of the tumor
with the deregulation of signaling pathways. Common
deregulation courses include PTEN inactivation by mu-
tation [39], de novo methylation of ER-α gene and aber-
rant methylation of CpG islands [1]. These epigenetic
alterations occur in a wide variety of tumors [8,40-44],
including endometrial cancer [36,45].
PR expression of either one or both of the two PR iso-
forms was found to be reduced or absent in endometrial
cancer [16-18,46], mostly lower for the higher histo-
logical grade [47-49] and inversely correlates with myo-
metrium invasion [50,51]. Our results demonstrate that
PR-A shows the exact same pattern of expression as ER-α
in the gland and stroma cells, as well as in the different
portions of EC specimens (Figure 2). It is well docu-
mented in the literature that the transcription of PR
gene is induced by estrogen and inhibited by progester-
one in the majority of estrogen responsive cells, so the
expression of ER and PR is considered to be coordinated
[27,37,52,53]. As described, we found significantly and
differentially altered expression of sex steroid receptors
in superficial and deep sections of the specimens. Previ-
ous reports, which support our findings, describe total
protein expression in the tissue. Our findings, describ-
ing the expression of PR-A and ER-α in the stroma andrficial, deep and extra-tumoral sections of EC
n of % positive cells) Ki67 (mean of % positive cells)
Deep Extra-tumoral Superficial Deep Extra-tumoral
1.7(±29.3) 93.7(±13.9) 45.7(±15.7) 28.3(±15.7) 2.3(±2.2)
0-100 50-100 10-70 5-50 <1-10
Table 2 Scoring of ER-α, PR-A and Ki67 in epithelium of non-malignant endometrial specimens
Patient num. ER-α (mean of % positive cells) PR-A (mean of % positive cells) Ki67 (mean of % positive cells)
08-23394 100 100 50
08-27832 100 100 <1
08-26747 80 100 25
08-28158 100 100 50
08-27037 40 0 <1
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genic response of epithelial cells to estrogen, which is
mediated indirectly by stromal ER [54]. A model for this
assumption was demonstrated by co-culture of non-
expressing ER stroma cells and ER-positive epithelial
cells [55]. No epithelial proliferation in response to es-
trogen was detected in this model, or in a model of pureFigure 1 Expression of ER-α in EC. Representative sections of the superfi
were stained with anti-ER-α antibody and compared with stained sections
photographs (A). The expression level was examined in epithelial cells (B),
stroma) (D) was calculated. Asterisks mark statistical significance (P < 0.05) cepithelial cultures, an induction observed in co-cultures
of normal uterine stroma and epithelial cells [55]. Evi-
dently estrogen induced epithelial proliferation requires
an ER-positive stroma. Response of uterine epithelial
cells to progesterone was also found to be mediated by
stromal PR [56]. This mediated operation between the
cells may be implicated and result in the altered patterncial (Block 1), deep (Block 2) and extra-tumoral portion (Block 3) of EC
of nonmalignant endometrial specimens (Normal), as seen in the
stroma cells (C) and the relative expression of both cell types (epithel/
ompared to nonmalignant endometrial tissue (normal) (X400).
Figure 2 Expression of PR-A in EC. Representative sections of the superficial (Block 1), deep (Block 2) and extra-tumoral(Block 3) portions of EC,
as well as nonmalignant endometrial specimens (Normal) were examined for PR-A expression, as seen in the photographs (A). The expression
level was examined in epithelial cells (B), stroma cells (C) and the relative expression of both cell types (epithel/stroma) (D) was calculated.
Asterisks mark statistical significance (P < 0.05) compared to nonmalignant endometrial tissue (normal) (X200).
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in our study. In addition to the well-known growth inhi-
biting effect of progesterone, it plays an important role
in regulating invasive properties of endometrial cancer
cells. A correlation was found between decreased PR ex-
pression in EC tumors and the expression of E-cadherin
and myometrial invasion [57,58]. An extensive myome-
trial invasion may be a progeny of epithelial to mesen-
chymal transition (EMT) which is highly implicated in
EC tumors invasive characteristics [59,60]. Therefore,
the reduced expression of ER-α and PR-A in the tumor
cells, particularly the significantly reduced expression in
the stroma cells, may indicate an invasive characteristics
of the tumor, as described for ER-α [61], and the deep
portion of the tumor is of special interest. These find-
ings in both superficial and deep portions of the tumorstand against the extra-tumoral portion of the tumor,
which was found to be affected as well, but to a lower
extent. PR-B quantification showed reduced expression
in the epithelial glands of superficial and deep portions
of EC (Figure 3). Supporting our findings, PR-B pro-
moter was previously found to be methylated in endo-
metrial carcinoma [62] and the loss of expression was
referred to as an independent prognostic factor for
cause-specific survival in high risk patients [63]. The
significantly high expression of PR-B in the extra-
tumoral portion of the malignant specimens may imply
a certain protective reaction opposing invasive properties
of the tumor cells. In a study conducted by Balmer NN et al.
[64], in which tumoral- and extra-tumoral- portions were ex-
amined by immunohistochemistry, resembling the current
study methodology, PR-B expression was found to be
Figure 3 Expression of PR-B in EC. PR-B expression was assessed in the superficial (Block 1), deep (Block 2) and extra-tumoral (Block 3) portions
of EC, as well as nonmalignant endometrial specimens (normal), as seen in the photographs (A). The expression level was examined in epithelial
cells (B) and in the stroma cells (C). Asterisks mark statistical significance (P < 0.05) compared to nonmalignant endometrial tissue (normal) (X400).
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nant endometrium compared to endometrial carcinoma.
Zafran et al. [65] found that a state of PR-B dominance,
like in the cell line HEC-1A, was less invasive than cell
lines that PR-A is the predominantly expressed variant.
PR-A may be associated with a cell- and promoter spe-
cific repression of PR-B [66] and imbalance in PR-A to
PR-B ratio is frequently associated with carcinogenesis
[67]. The relative over-expression of PR-B, which is re-
ferred to as an endometrial estrogen agonist [68], with-
out transcriptional repression by PR-A, as shown in our
findings, may also be related to the metastatic potential
and partially cause deviation from sex steroidal depend-
ency in endometrial cancers [33]. Our results show
higher expression of Ki-67 in the malignant tissue
than in the nonmalignant, as seen in previous studies
[22-25,69]. A wide score range of Ki67 expression was
found in the non-malignant biopsies. These results correl-
ate with the expression of Ki67 in normal cyclical endo-
metrium, in which Ki-67 staining is intense and diffused
in the proliferative phase, but decreases dramatically in
the early and mid-secretory phase.
Conclusions
In the current study, we have showed the importance of
referring to steroid receptors profile in the stroma as
well as the epithelial cells. The problem in attaining aconsensus regarding assessment of endometrial carcin-
omas was recently discussed [70,71] and updating the
pathologist biomarkers panel was shown to be useful
in characterizing EC tumors and in patients prognosis
[72-74]. Studies of steroid receptors pattern of expres-
sion help in understanding their mechanism of action in
target tissues, and could be helpful in defining biologic-
ally different subgroups and therapeutic efficacy. We
have found that the ratio of ER-α and PR-A expressions
in the epithelial glands and the stroma of EC biopsies
has a distinct values in different portions of the tumor.
These findings may serve in the marker panels of the
pathologist in order to improve diagnostic reproducibil-
ity. It should be noted that this study has focused on a
small and limited group of biopsies. Further analysis in
large scale study may contribute to the understanding of
ER and PR isoforms expression in EC, and a possible use
of ER-α and PR-A relative expression as a clinical tool.Additional file
Additional file 1: Patients epidemiological and pathological data.Abbreviations
EC: Endometrioid carcinoma; ER: Estrogen receptor; PR: Progesterone
receptor; EREs: Estrogen response elements; FFPE: Formalin fixed
paraffin-embedded; EMT: Epithelial to mesenchymal transition.
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